NanoViricides Inc. (NNVC)

[changes_iv]

another_voice_2, keep in mind, my post is composed of one sentence of mine directed to "Pump Terminator" and a hours old excerpt from an article published in naturalnews.com. Re-post at will or re-post just the article excerpt with the link to the full article in naturalnews.com.

Now that it seems the nation is flying in the fog without instruments against an Ebola storm, here is another local news article from Italia.

Uproar over US troops' Ebola quarantine in Italy

The decision to put a dozen American soldiers returning from Liberia into quarantine for Ebola at their base near Venice rather than in the United States sparked controversy in Italy on Wednesday.
.
.
.
"The government must send all the US soldiers back to Washington," the anti-establishment Five Star party said, according to media reports.

Not only was information about the current state of health of the soldiers "limited to general reassurances from the American authorities", but there were fears other soldiers on the base "may have been in contact" with those returning from west Africa, they said.

http://www.thelocal.it/20141029/us-soldiers-ebola-quarantine-in-italy-sparks-alarm

Why not have our American soldiers here in the U.S.? The Federal government could turn those empty buildings in Washington D.C. into state-of-the mandatory quarantine facilities. If Texas can build two state-of-the-art hospitals, can we build several state-of-the-art quarantine facilities. How about some of that "yes we can attitude" for our soldiers? Fired up, ready to go!

Imagine the photo up opportunities for big government types, http://www.sciencedaily.com/releases/2013/08/130821152059.htm, just like the one worn by Gene Olinger (image below).



Here is how NanoViricides, Inc. will save the day...

NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today
.
.
.
The Company had previously developed anti-Ebola drug candidates that demonstrated the validity and potential of the Company's approach, based on cell culture and animal testing conducted at US Army Medical Research Institute of Infectious Diseases (USAMRIID) in a BSL-4 facility. The Company had to de-prioritize this development in order to focus on the development of its lead drug candidate, Injectable FluCide™, for treatment of hospitalized patients with influenza. The Company has recently reported that it has restarted its anti-Ebola/Marburg drug program, in consideration of the severe public health impact of an Ebola virus epidemic. The current outbreak in Africa has unequivocally demonstrated the need for an effective, broad-spectrum, anti-Ebola therapeutic.

The Company has now developed additional novel drug candidates against Ebola that it believes could lead to a successful therapeutic. A nanoviricide® drug is made up of two components that are chemically connected together: a virus-binding ligand that mimics the native receptor on the host cell to which the virus binds, and a backbone polymer that makes the nanoviricide "look like" the host cell surface to the virus. There have been significant developments in the elucidation of the important cell surface receptors and attachment factors of Ebola virus recently. With this new structure based information, the Company has been able to redesign its anti-Ebola ligands.

"We believe the new anti-Ebola ligands should make the new drug candidates substantially superior to our older ones, based on the molecular modeling studies we have conducted using the structural information of interaction of Ebola virus glycoprotein with its cellular receptor Niemann-Pick C1 protein," said Anil R. Diwan, PhD, President of the Company, "We believe that Ebola virus will not be able to avoid our drug candidates in spite of mutations, because we are mimicking NPC1, the receptor to which the virus must bind in order to infect the host cell. Of course, we must await results from actual cell culture and animal testing to further develop these candidates."

http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html

We are only days away from the second generation EbolaCide efficacy testing start.